1. Home
  2. Product Information
  3. Dalbavancin

Product Information

Dalbavancin

Class Glycopeptide anti-MRSA antibiotic
Mechanism of Action Cell Wall Peptidoglycan Synthesis Inhibitor
Target Indication MRSA Infections
Overseas Development Status Marketed (Dalvance)
Portfolio for development and marketing rights in Japan
Product Summary

Dalbavancin is a new glycopeptide anti-MRSA* antibiotic. Compared to existing glycopeptides anti-MRSA antibiotics, it has better antibiotic strength and, because it only needs to be taken once a week, it will be easier for both patients and medical care providers. It also offers stable absorption and metabolism for patients with light to moderate kidney and liver dysfunction. We know that its interactions with other medications are extremely small, and it is proving to be very safe in clinical trials.

*MRSA: Methicillin-Resistant Staphylococcus Aureus

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics